Developing both prophylactic 
and therapeutic effective 
countermeasures

Crimean Congo Haemorrhagic Fever 
Vaccine & Immunotherapy

The CCHFVACIM project aims to address the serious public health threat posed by Crimean Congo Haemorrhagic Fever Virus (CCHFV), a tick-borne zoonotic virus that causes fatal epidemics in humans. This is one of the most threatening vector-borne pathogens, widely distributed, including on the European continent. Currently, there are no preventive or effective therapeutic measures available against CCHFV, which is listed as a key priority in the WHO’s R&D Blueprint list of infectious agents with epidemic or pandemic potential.

Deep structural biology studies on viral glycoproteins and investigation of the immunogenicity of the viral antigens will be combined with optimisation of a mRNA vaccine candidate against the virus and characterisation of the resulting protective immunity, as well as with the development of immuno-therapeutic monoclonal antibodies (mAbs) based on CCHFV’s antigenic targets.


Numbers

0

partners

0

countries

0

years EU-funded

project

0M

€

News

  • Science & collaboration highlights

    Advancing research and collaboration in CCHFV preparedness. CCHFVACIM is driving forward cutting-edge research through a collaborative, multidisciplinary approach to pandemic preparedness. During the first phase of the project, important scientific advances have been achieved, including the characterization of key viral structures and immune responses, as well as the identification of promising vaccine targets. The project…

  • Recently published on CORDIS

    CCHFVACIM Builds on EU Research to Advance a Vaccine Significant progress has been made in the global fight against Crimean-Congo Haemorrhagic Fever (CCHF) — a severe tick-borne viral disease with fatality rates that can reach 40 % and no licensed vaccine available. CCHF is transmitted to humans through the bite of infected Hyalomma ticks, and…

  • Project milestones & first achievements

    CCHFVACIM reaches key milestones in its first reporting period. The CCHFVACIM project has made significant progress during its first reporting period (January 2024 – June 2025), laying strong foundations for the development of innovative vaccines and immunotherapies against Crimean-Congo Haemorrhagic Fever (CCHF). Among the key achievements, the consortium successfully designed and evaluated multiple mRNA-based vaccine…